Most recent update: Monday, December 9, 2019 - 16:52

Bariatric News - Cookies & privacy policy

You are here

Endoscopic Sleeve Gastroplasty (ESG)

Enrolment completed in endoscopic sleeve gastroplasty MERIT study

Apollo Endosurgery has announced that the final patient has been enrolled in the Multi-Center ESG Randomized Interventional Trial (MERIT), the US-based, prospective randomised multi-centre-controlled trial is evaluating the effectiveness of the endoscopic sleeve gastroplasty (ESG) procedure.

Five-year ESG outcomes reveal significant total body weight loss

Endoscopic sleeve gastroplasty (ESG), a relatively new, minimally invasive weight-loss procedure, resulted in significant total body weight loss in the first long-term study to follow patients' progress over five years, according to research - ‘Long-term follow up and outcomes after endoscopic sleeve gastroplasty for treatment of obesity (5-year data)’ (abstract 70) - were presented Digestive Disease Week (DDW) 2019.

Apollo initiates Spanish Endoscopic Sleeve Gastroplasty NASH study

Apollo Endosurgery has enrolled first patient in a multi-centre, randomised, controlled, double-blind study of the efficacy and safety of Endoscopic Sleeve Gastroplasty (ESG) using Apollo’s OverStitch Endoscopic Suturing System, in patients with non-alcoholic steatohepatitis (NASH). The study is funded by a Beca FIS Grant awarded to the Foundation of the Hospital Universitario Puerta de Hierro Majadahonda by the Ministry of Health of the Spanish Government.

Subscribe to RSS - Endoscopic Sleeve Gastroplasty (ESG)